EGFR and lung adenocarcinoma: The mutation rate of EGFR in SqCLC is notably lower than in lung adenocarcinoma (LUAD), and SqCLC generally exhibits a poorer response to EGFR tyrosine kinase inhibitors (TKIs) (8).